FDA approves Boehringer's once-a-day inhaler drug

July 31, 2014

(AP)—The Food and Drug Administration has approved a new long-acting inhaler drug from Boehringer Ingelheim to treat people with chronic lung disease.

The agency approved Striverdi Respimat for chronic , which causes bronchitis and emphysema and affects about 24 million people in the U.S. The disease, which is most often caused by smoking, is the third leading cause of death in the U.S., according to the National Institutes of Health.

The FDA approved the drug on Thursday based on a study in 3,104 patients which showed improvements in lung function versus placebo.

The drug will carry a bold warning that it is not approved to treat patients with asthma. Striverdi Respimate is part of a family of medications that have been linked to asthma-related deaths.

Related Stories

Tudorza pressair approved for COPD

July 24, 2012

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) ...

Adempas approved to treat pulmonary hypertension

October 9, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Opsumit approved for pulmonary arterial hypertension

October 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Anoro ellipta approved for COPD

December 18, 2013

(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.